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Abstract    
In the last few years, our research group has focused on the design and development of 
plasmid DNA (pDNA) based systems as devices to be used therapeutically in the 
biomedical field. Biocompatible macro and micro plasmid DNA gels were prepared by 
a cross-linking reaction. For the first time, the pDNA gels have been investigated with 
respect to their swelling in aqueous solution containing different additives. Furthermore, 
we clarified the fundamental and basic aspects of the solute release mechanism from 
pDNA hydrogels and the significance of this information is enormous as a basic tool for 
the formulation of pDNA carriers for drug/gene delivery applications. The co-delivery 
of a specific gene and anticancer drugs, combining chemical and gene therapies in the 
treatment of cancer was the main challenge of our research. Significant progresses have 
been made with a new p53 encoding pDNA microgel that is suitable for the loading and 
release of pDNA and doxorubicin. This represents a strong valuable finding in the 
strategic development of systems to improve cancer cure through the synergetic effect 
of chemical and gene therapy. 
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Introduction   
The evolution in the design and preparation of hydrogels, namely at the micro and 
nanoscale, has a great deal of interest in biomaterials science because of their tunable 
chemical and physical three-dimensional structure, good mechanical properties, high 
water content and biocompatibility to tissue and blood.
1-6
 These characteristics give 
potential value for the use of hydrogels in biomedical implants, tissue engineering, 
bionanotechnology and drug/gene delivery.
7-11 
Concerning this last issue, a major 
research thrust in the biochemical/pharmaceutical technology is still the development of 
efficient and safe controlled release systems for the sustained delivery of drugs and 
bioactive agents. To be used therapeutically, these systems should be able to deliver the 
drug and/or gene at a specified rate and time period ensuring that the concentration of 
the biopharmaceutical in the body would be kept in the desirable range for a prolonged 
time. Additionally, the carrier can be targeted to a particular cell type or an organ;
12-14
 
not only protein drugs would benefit from a targeted delivery to their site of action, but 
also highly toxic ones such as anticancer drugs.
15-19
 The creation of polymer networks 
tailoring intrinsic properties, such as, ionization of the gel, the extent of swelling and its 
reversibility, and specific mesh size appears as a valuable tool in engineering 
appropriate release devices. Development of temperature-responsive hydrogels,
20,21
 pH-
responsive networks
22
 and glucose-responsive hydrogels
23,24 
were conceived to improve 
the field of sustained/controlled drug delivery. In order to enhance their practical 
efficacy in the biomedical area, mathematical models can be applied to correlate 
material properties, interaction parameters, kinetic events, and transport behaviour 
within complex hydrogel systems.
25-27 
Among the several physical/chemical properties 
of hydrogels that can be manipulated to ensure greater delivery performance, both the 
gel swelling and biodegradability are remarkable strategies. The swelling is restricted by 
the cross-linking density in the network and the deswelling by the volume occupied by 
the polymer network. There are several studies in the literature reporting the controlled 
release of drugs from biodegradable hydrogels,
28,29
 such as the release of recombinant 
human interleukin-2 from dextran-based hydrogels;
30 
similar dextran hydrogels were 
investigated as drug delivery devices for the posterior part of the eye.
31 
Moreover, the 
polymer hyaluronic acid (HA) was used to create a combination tissue engineering 
scaffold and protein delivery vehicle.
32 Recently, in situ forming biodegradable 
poly(ethylene glycol) based hydrogels were created for the time-controlled release of 
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tethered peptides or proteins
33
 and injectable biodegradable hydrogels were studied as 
vehicles for the release of anticancer drugs.
34 
Biodegradable hydrogels appears to be 
quite suitable for DNA release, once one can readily control the release rate by 
modulating the network structure with adjusting cross-linking density.
35,36 
  
The field of gene therapy, with either viral or synthetic vectors, attracts great and 
widespread interest, due to its technological challenging characteristics and for 
providing great opportunities for treating diseases due to genetic disorders, infections 
and cancer.
37 
The use of synthetic vectors is an incredible improvement and has many 
assets, such as, ease and variability of preparation; lack of immune response and 
unlimited DNA-carrying capacity.
38,39
 Controlled gene release ensures the increase of 
the extent and duration of transgene expression, reduced need for multiple interventions 
and lower toxicity to non-target cells.
40-47 
Applied to cancer treatment, gene therapy 
purposes using hydrogel devices bring impressive progresses feeding the hope of cancer 
cure.
48-52
 Several interesting studies reporting the efficiency of p53 gene cancer therapy 
are available in the literature.
53-58  
In line with this, and in an attempt to evolve in the 
cancer cure, a new strategy seems to be the combination of chemical and gene therapy 
improving the treatment efficacy due to their synergistic effect. Simultaneously with 
anticancer drugs, specific genes can be delivered to the same cancer cells to enhance 
sensitivity of targeted cells to drug, during all the treatment. Over the past decade, a few 
studies reporting the delivery of nucleic acids and drugs have been presented,
59-63
 
illustrating the advantage of its combined effect in medical care. This bifunctionality 
may represent an enormous advance in comparison to individual chemotherapy 
treatments and will, certainly, serve as a basis to improve cancer therapies. Recently, a 
new p53 encoding plasmid DNA (pDNA) microgel that is porous, biocompatible, and 
photodegradable, thus suitable for the loading and release of pDNA and, e.g., 
doxorubicin, an intrinsically fluorescent anticancer drug widely used in cancer 
treatment, has been developed.
64 
  
This review represents our contribution to the field of biomaterials design, and concerns 
the synthesis of new plasmid DNA vehicles with potential biomedical application. The 
interesting features found in the proposed systems ranged from responsive swelling 
properties, light triggered release profile and promising drug/gene co-delivery approach 
in cancer therapeutics.  
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Plasmid DNA gels formation and characterization  
In the last decade, we assisted to a growing knowledge in the scientific area dealing 
with delivery systems of nucleic acids. In an attempt to better understand DNA 
trafficking and expression, new strategies based on liposomal
65-73
 and polymeric
74-85 
formulations emerged for the efficient delivery of theses vectors toward cells. Our 
group focused on the synthesis of chemical pDNA based hydrogels by cross-linking 
reaction with ethylene glycol diglycidyl ether (EGDE). The reaction mechanism of gel 
formation seems to involve the guanine nitrogen atom at position seven (N-7), which 
attacks the more substituted carbon of the epoxide or the least hindered end of the 
epoxide. The reaction is of nucleophilic substitution type (SN2 reaction). All pDNA gels 
are clear and transparent (Figure 1). The knowledge of the equilibrium degree of 
swelling allows for the calculation of matrix structural parameters such as the distance 
between cross-links and the mesh size of the gel. Gels with different cross-linker 
densities were prepared.
86
 Following the method of determination described by Canal 
and Peppas,
87
 the mesh size has been determined.
88
 Information about the integrity of 
double helix of the DNA molecules in the gels was obtained by fluorescence 
microscopy using acridine orange (AO), as a dye.
89,90
 AO intercalates into double 
stranded DNA as a monomer, whereas it binds to the single stranded DNA 
conformational state as an aggregate. Upon excitation at 470 nm to 490 nm, the acridine 
orange monomeric form binds to ds-DNA and fluoresces green. The aggregated acridine 
orange on ss-DNA fluoresces red.
91 
Through the observation of green or red 
fluorescence, DNA fluorescence microscopy studies with AO have revealed the DNA 
conformational state in the gels. Figure 2 shows fluorescence micrograph (A) and 
scanning electron micrograph (B) of a plasmid DNA gel, respectively. Both images 
demonstrated that the gels show a porous and smooth surface. Fluorescence microscopy 
studies have also revealed that the formation of the gels was carried out with the 
conservation of plasmid DNA double helix integrity. Complementary, scanning electron 
micrographs allow to conclude that those gels show a three-dimensional coral-like 
spongy structure with small cavities confined by perforated membranes. Moreover, cell 
viability assays suggested that the pDNA gels are non-toxic to cells and this step 
contributes to the possibility of using them as carriers in real biological systems. As 
expected, toxicity increases with cross-linking density.
86 
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Swelling behaviour of Plasmid DNA gels  
In pure water, charged networks swell due to the osmotic pressure from the counterions, 
which originates from their translational entropy. The driving force of the swelling 
process is the presence of mobile osmotically active counterions. The volume changes 
of gels are associated with osmotic effects and not dehydration.
92-95
 he extent of the 
collapse is affected by molecular parameters of the network such as the cross-linking 
density, the hydrophobic/hydrophilic balance of the polymer network, its content of 
charged groups, its flexibility and its ability to interact with added solutes. In neat water, 
the degree of swelling for 0.2% EGDE plasmid DNA gels is considerably larger than 
that of corresponding 0.5% EGDE gels. A lower cross-linker density leads, as expected, 
to an increased swelling. An increase in the level of cross-linking agent leads to a larger 
resistance to the osmotic swelling force and thus to a reduced equilibrium swelling.
86  
Furthermore, the swelling behaviour of covalently cross-linked pDNA on addition of 
different cosolutes, which include inorganic salts with different cation valency, 
polyamines such as spermine and spermidine, cationic macromolecules such as 
lysozyme and chitosan, and different classes of surfactants was studied.
86  
On addition 
of a monovalent electrolyte, there is a progressive contraction of the gels. When gels, 
preswollen in the 1 mM NaOH, are placed into salt solutions at different concentrations, 
they shrink due to the screening effect of the salt and mainly due to the concentration 
difference of mobile ions inside the gel and the external solution governed by the 
Donnan equilibrium. In the presence of salt, the difference between ion concentrations 
inside and outside the gel is reduced. Consequently, the driving force of swelling 
decreases gradually with increasing salt concentration. In addition, Pourjavadi et al. 
recognized the lower absorbent capability of hydrogels in the presence of salts and 
proposed a parameter to measure the salt effect on the water absorbency capacity by 
correlating the hydrogel swelling in pure water and that in a salt aqueous solution.
96   
The nature of the monovalent counterion has only a moderate effect on the deswelling 
of plasmid DNA gels. The degree of collapse follows the order Na
+
 > K
+
 > Rb
+
 > Cs
+
, 
with the sodium ion showing the highest ability in collapsing pDNA gels.
86
 The order 
observed suggests that monovalent cations with a smaller ionic radius are more efficient 
in the collapse of pDNA gels. It is known that monovalent alkali cations are involved in 
the regulation of important biological processes and also influence the DNA compaction 
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in living cells. Compaction of DNA by monovalent cations alone does not occur but can 
be promoted by an increase in the concentration of monovalent salts.
97
 Studies of the 
influence of the cation nature on the ability to induce DNA compaction in solution have 
been performed.
98 
The deswelling on addition of the divalent salts CaCl2, MgCl2 and 
SrCl2 occurs at considerably lower salt concentrations and the deswelling appears to be 
more pronounced, as compared with the monovalent metal ions. The collapse ratios for 
these gels show a trend in the order CaCl2 > MgCl2 > SrCl2, with calcium being the 
most effective ion in collapsing plasmid DNA gels.
86 
Concerning the poly-cationic 
species chitosan, spermine (Spm), spermidine (Spd) and lysozyme, it was found that 
chitosan is the most efficient co-solute in promoting the gel collapse, followed by the 
polyamines and finally lysozyme. The different charges carried by these cationic species 
confer them characteristic swelling behaviour. The higher charge of spermine compared 
to spermidine evidently makes spermine bind more strongly to pDNA with a 
concomitant higher gel collapse potential. A considerably larger concentration of 
lysozyme was needed to reach a corresponding collapse of the gel, than for the other 
polycationic species. Lysozyme has a rather low density of surface charges, since the 
cationic groups are located among uncharged and anionic amino-acid residues on the 
protein surface. A contribution to the difference can also comes out from steric effects, 
i.e., a linear polymer penetrates more easily into the network than a globular one.   
In the bulk phase and at low concentrations, the surfactant molecules are dissolved as 
unimers, whereas at higher surfactant concentrations a self-assembly into aggregates 
occurs. For the single-chain surfactants, the aggregates formed in this self-assembly are 
commonly spherical micelles with micelle formation starting at a well-defined 
concentration, the critical micelle concentration (cmc).
99
 In the presence of an 
oppositely charged polyelectrolyte, the micelle formation of an ionic surfactant is 
strongly facilitated leading to a major lowering of the cmc.
100
 The stabilisation of 
micelles due to an oppositely charged polyelectrolyte is mainly an entropic effect, due 
to a release of counterions.
101-105
 As expected, the cationic surfactant binding is 
particularly strong for anionic polyelectrolytes of high charge density.
101 
The plasmid 
DNA gels are highly swollen due to the osmotic pressure arising from the counterions, 
which are confined to the gel. After the immersion of the swollen pDNA gels in the 
solutions of the oppositely charged surfactants, the surfactant ions migrate into the 
network and replace the network counterions, which are released. Adsorption of a 
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considerable amount of CnTA
+
 ions leads to a transition of the swollen network to the 
collapsed state. The main reason for this transition is thus the aggregation of surfactant 
ions within the pDNA gel due to hydrophobic interactions between their hydrocarbon 
chains.
 
As a consequence of this, the mobile counterion concentration in the network 
decreases, leading to a significant decrease in the internal osmotic pressure in the gel. 
Furthermore, the surfactant aggregates will act as multivalent counterions and by ion 
correlation effects contribute to the contraction of the gel. Figure 3 shows swelling 
isotherms for plasmid DNA gels on addition of a number of cationic surfactants. The 
surfactants have no effect at lower concentrations but there is a marked deswelling at 
higher concentrations, which becomes more important the longer the surfactant alkyl 
chain. The concentration of onset of deswelling varies by orders of magnitude between 
different surfactants; additionally, the plateau value obtained at high surfactant 
concentrations is lower by increasing the alkyl chain length.
86 
The pronounced chain 
length dependences directly suggest a dominant role of surfactant self-assembly. These 
results for the different alkyl chain lengths confirm that the deswelling occurs below the 
normal critical micelle concentration of the surfactant. The cmc values for C16TAB, 
C14TAB, C12TAB and C8TAB are 0.9 mM, 0.23 mM, 15 mM and 144 mM, 
respectively. We found that the surfactants induce the volume transition starting at a 
certain rather well-defined concentration, critical association concentration, cac ~ 0.015 
mM for C16TAB, cac ~ 0.045 mM for C14TAB, cac ~ 0.08 mM for C12TAB and cac ~ 1 
mM for C8TAB.
120 
Furthermore, the swelling of the gels appears to be reversible, as 
exemplified by the deswelling/swelling process induced by consecutive addition of 
cationic and anionic surfactant. The relative V/V0 returned to between 90 and 100% of 
the initial state. The interaction between the two surfactants is stronger than that 
between a cationic surfactant and plasmid DNA. The dynamic deswelling-swelling 
process could be useful in the control of the release rate of solutes from gels via “on-
off” switching.  
 
Light triggered release from Plasmid DNA gels  
Our expertise on the gel swelling behaviour, compaction of DNA by cationic entities, as 
lipids and surfactants as well as on the assembly structures of these complexes allow us 
for the development of novel systems to be used in a variety of biomedical 
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applications.
36,86,106-113 
Once the physicochemical characterization of pDNA hydrogels 
has been established,
86
 we evolved to the challenge of using pDNA-based carriers in the 
biological area. During the research of pDNA gel as delivery system it was found that 
the pDNA network is photodegradable.
88
 The first evidence of gel degradation comes 
from the pDNA release after gels being irradiated with light. After irradiation, both gels 
with different degrees of crosslinking (0.2 % and 0.5 % ethylene glycol diglycidyl ether 
(EGDE)) suffered disruption leading to the release of plasmid DNA with time (Figure 
4). The release is characterized by a narrow time lag in the first 24 hours, after which 
the release gradually increases until a plateau is reached around 400 hours of 
photodegradation. The initial time lag, 18 and 23 hours for 0.2 % and 0.5 % EGDE gels 
respectively, may be related to the number of cross-links that have to be degraded to 
permit the release of plasmid DNA. After irradiation, and at maximum release, pDNA 
gels cross-linked with 0.2 % EGDE released 87.8 % of plasmid DNA while gels 
prepared from 0.5 % EGDE released 74.7 % of pDNA, in approximately 18 days. In the 
absence of ultraviolet light irradiation, and for both gel types, minimal amounts of 
pDNA, less than 8 %, are released. The degradation on ultraviolet light exposure 
(photo-oxidation) leads to the removal of the chemical cross-links and can allow the 
release of the constituent network polymer inducing changes in gel weight, mechanical 
properties, mesh size, porosity, and in the degree of swelling.
88 
 
In degradable gels, if the release of solutes is governed by polymer degradation, the 
degradation rate of the hydrogel must be matched to the size of the solute species. 
Moreover, control of variations with mesh size in time is crucial to design appropriate 
solute release devices. During hydrogel degradation, the water content tends to increase, 
increasing both the network mesh size and the volume swelling ratio and, consequently, 
the release of gel entrapped solutes is facilitated. To evaluate the dependence of the 
release rate on the size of an entrapped solute, lysozyme, BSA and FITC-dextran with 
molecular weights ranging from 14 100 to 77 000 Da, and the hydrodynamic radius 
being 16, 34.8 and 55 Å, respectively, were incorporated into 0.2 % and 0.5 % EGDE 
cross-linked pDNA gels.
88 
The effect of radiation, on the release profiles of these 
molecules is presented in Figure 5. From the release curves it is possible to infer that 
approximately 98.6 % of lysozyme, 94.9 % of BSA and 96.6 % of FITC-dextran are 
released in 48, 192 and 274 hours, respectively, from 0.2 % EGDE pDNA gels. 
Similarly, approximately 94.9 % of lysozyme, 93.1 % of BSA and 94.1 % of FITC-
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dextran are released in 72, 240 and 300 hours, respectively, from 0.5 % EGDE pDNA 
gels. In order to have a deep assessment on the release mechanism, the release kinetics 
has been fitted to Equations (1) and (2). Equation (1) is the simple power law 
Korsemeyer-Peppas equation
114
  
Ct/C∞ = kt
n
   (1) 
where Ct and C∞ are cumulative concentrations of the material released at time t and at 
infinite time, respectively, and k and n are fitting parameters, giving the later useful 
information on the release mechanism; for the release from cylinders (spheres/thin 
films), values of n near 0.45 (0.43/0.5) indicate a diffusion-controlled release (so-called 
Fickian). Non-Fickian behaviour is observed for 0.45 < n < 0.89 (0.43 < n < 0.85 / 0.5 < 
n < 1.0), with a limit of Case II (zero-order release) transports for n = 0.89. Non-Fickian 
and Case II transport are indicative of coupling of diffusional and relaxational 
mechanisms. Occasionally, values of n > 0.89 (0.85/1.0) has been observed and 
considered to be Super Case II kinetics.
114 
An empirical approach, which allows 
describing the entire set of the release data, is based on the Weibull function 
[1 exp( ' ) ]dtC C k t      (2) 
where k’ and d are constants. Papadopoulou et al.115 have demonstrated that eq. (2) 
gives an insight into the diffusional mechanism, since the d and k’ are closely related to 
the mechanism and rate constant of release, respectively. For BSA and FITC-Dextran n 
values are higher than 0.89 indicating a Super Case II release phenomena. This is also 
confirmed by d (Eq. 2) values higher than 1.
88
 This mechanism emerges as the polymer 
resistance becomes more significant relative to the diffusion resistance; consequently, 
the release is linear at early times in the process, but at long time the release rate 
increases markedly. For the release of lysozyme, the analysis of the exponent d, 
suggests a Fickian release process. From the analysis of the release rate (k’) of 
lysozyme, BSA and FITC-dextran from pDNA gels with different degrees of cross-
linker we found that: a) k’ decrease by increasing the degree of cross-linker and, b) for 
both gels, k’ decreases from lysozyme to FITC-dextran by changing ca. two orders of 
magnitude.
88 
Additionaly, for both cross-linker densities pDNA gels there is a 
correlation between the gel mesh size and the solute size. Not only drug size is 
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important but also the mobility of polymer chains and the extent of swelling are factors 
that should be taken into account.
88  
 
To further demonstrate the sustained release characteristics of the pDNA gel system, 
release studies were evaluated in vitro using selected anti-inflammatory drugs 
(hydrocortisone, cortisone, prednisolone, dexamethasone and prednisone). Modelling of 
the in vitro release profile is consistent with a Super Case II release mechanism, related 
with increases in the gel swelling degree. Furthermore, the release of the anti-
inflammatory drugs depends on the balance between hydrodynamic volume and 
hydrophobicity and there is a correlation between drug release rate constant (k’) and the 
hydrophobicity as quantified by the octanol-water partition coefficient; a slow release 
rate was found for the more hydrophobic drugs.
88 
This shows that this biomaterial can 
be quite useful as a controlled release device for several therapeutic agents at wound 
sites.                                                    
Other authors took advantage of the photodegradable property to develop drug 
controlled release systems as valuable technology to be applied in the biomedical field. 
Han´s group designed photodegradable block copolymer micelles as nanocarrier for 
light-triggered release of guest molecules, which offers the remote-control possibility 
and enhances selectivity.
116
 Other strategy with diblock copolymers has been used to 
promote in vitro photo-controlled drug delivery.
117
 Fairbanks et al. synthesized 
hydrogels for the delivery of therapeutic agents as well as the study and manipulation of 
biological processes and tissue development. These gels are photodegradable and 
photoadaptable.
118
 In a study using polyurethane based nanoparticles, it was 
demonstrated the promising way to trigger drug release in cells.
119
 Considering that a 
deep penetration of nanosystems in tumors is required to increase its therapeutic value 
Tong and co-workers reported a novel photoswitchable carrier that provides 
spatiotemporal control of drug release and enhanced tissue penetration.
120 
 In the same 
issue, photodegradable macromers and hydrogels allow for live cell encapsulation and 
release.
121 
Furtehrmore, for the first time the synthesis of photoresponsive polypeptide-
based block copolymers has been established adding new possibilities in 
nanomedicine.
122
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A therapeutical strategy based on drug/gene co-delivery  
Innovative strategies in cancer treatments can combine conventional approaches, as 
radiotherapy and chemotherapy, with the emerging gene therapy modality improving 
clinical achievements.
123,124
 Following this concept, we created a pDNA based system 
for the sustainable delivery of anticancer drugs and genes to cancer cells. The tumor 
suppressor gene p53 was efficiently encapsulated into biocompatible microgels by an 
inverse microemulsion polymerization method using ethylene glycol diglycidyl ether 
(EGDE) as cross-linker.
64
 (Figure 6) For 0.1% EGDE microgels, the diameter of 
spheres range from 0.5 to 2 μm; by increasing the cross-linker concentration, the size of 
spheres range from 1 to 5 μm, showing a higher heterogenous size distribution.64 High 
p53 encapsulation efficiencies were obtained. Moreover, it was demonstrated that the 
microgel structure protect the encapsulated pDNA against serum nucleases, which is an 
important issue affecting both pDNA stability and transfection efficiency.   
Doxorubicin (DOX) has been incorporated into pDNA gels by imbibition and, along 
with p53 gene, can be loaded and release from microgels; quite relevant is also the less 
toxic effect of the incorporated drug, as compared with naked DOX. Photodisruption of 
microgels can be used as a strategy to enhance release. Through a quantitative analysis 
using appropriate release models we found that the pDNA release follows a Super-Case 
II transport mechanism, while the doxorubicin is Fickian when the microgels were light 
irradiated.
64 
Furthermore it is worth noticing that the mean dissolution time
125
 of DOX, 
from irradiated pDNA microgels, is around 50 hours. Before being used in transfection 
studies, the pDNA microgels were irradiated with light (400 nm), in order to promote 
the microgel photodisruption and consequent release of pDNA. The p53 protein content 
has been determined by using the p53 pan-Elisa kit. This assay for the quantification of 
wild-type and mutant p53 is based on a quantitative sandwich Elisa principle. Figure 7 
presents the relative quantification of p53 protein expression in cancer HeLa cells 
transfected with 0.1% and 0.2% EGDE pDNA microgels, as a function of initial pDNA 
loading amount. We stated that 0.1% EGDE microgels are able to surpass the cellular 
barrier and release bioactive pDNA into the cytosol. The barrier of the nucleus is 
permeable to foreign pDNA only during cell division; the high rate of tumour cell 
division, probably, enhances transfection and gene expression. Contrary, for the most 
cross-linked pDNA vector the success of transfection is very limited since the 
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quantified p53 density is not significant. For this situation, contributes the mean 
diameter of 0.2% pDNA microgels which is too large for efficient intracellular uptake 
and internalization.
64
 It becomes clear the relevance of vector properties such as, size, 
cross-linker density and pDNA loading in the success of transfection process, of which, 
size seems to be the most important of all. Thus, the less cross-linked microgel carrier is 
more suitable for gene delivery applications since it demonstrates a good biological 
functionality for pDNA loading and in vitro gene expression. Additionally, a study 
using YOYO labelled p53 microgels illustrates the advantage of p53 encapsulation, as 
well as, the cell uptake/transfection efficiency of this pDNA carrier.
126
 
Cancer cells are usually quite resistant to apoptosis and the mechanisms underlying this 
resistance still remain, in most of the cases, unclear. The mitochondrial activity assay, 
MTT, is one of the few tools used to monitor apoptosis that provides quantitative rather 
than qualitative results. To evaluate the inhibition of cell viability and induced cell 
apoptosis by the pDNA studied systems, MTT assay was applied to Hela cells treated 
with naked pDNA, 0.1% EGDE pDNA-lipofectamine microgel or 0.1% EGDE 
pDNA/DOX-lipofectamine microgel (Figure 8).
126
 It is quite evident, from our studies, 
that the application of naked pDNA is not successful in grow inhibition or death of Hela 
cells. When cancer cells are exposed to p53 encoding plasmid DNA microgels a cell 
viability inhibition effect is observed; viable cells gradually decrease with transfection 
time, with a major lowering of 23% from day 4 to 6. This clearly indicates the 
expression of the p53 gene and its regulatory role associated with damaged DNA; the 
introduction of p53 into tumor cells leads to cell apoptosis. Compared with the 
treatments of p53 microgel and free drug separately, the simultaneous treatment by p53 
and DOX with the pDNA/drug microgel has a stronger effect in reducing cell viability. 
Co-delivery of gene and drug to the same cells results in efficient cell inhibition and 
larger apoptosis, and thus p53/DOX microgels are able to effectively mediate gene 
transfection and drug release enhancing curing effect. The dual delivery vehicle exhibits 
lower percentage of viable Hela cells, illustrating the achievement of clear synergistic 
effect in suppressing the proliferation of tumor cells when compared to individual 
treatments of encapsulated p53 and pure DOX.
126
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Conclusions and future trends   
In this review, we have summarized the progresses achieved by our research team in the 
biomedical field by using plasmid DNA based systems. This is our contribution to the 
advance in engineering cross-linked networks with suitable intrinsic properties for 
studying plasmid DNA/co-solutes interaction, in general, and for the dual delivery of 
genes and drugs. These pDNA gel carriers can found interesting applications as 
biomedical devices in a variety of clinical purposes. Although there has been a lot of 
significant work developed, in the last decades, aiming the targeted and controlled 
release of plasmid DNA there are still many issues to address, namely target the 
delivery of these vehicles to specific organs, tissues and cells. The future of colloidal 
research holds for the development of novel innovative matrices with controlling 
mechanical viscoelastic properties, versatile swelling performance, size and internal 
organization, triggered degradation behaviour, as well as for enhancing their biological 
interactions with body components to design and tailor appropriate devices to be used 
therapeutically. Furthermore, a continuous search for understanding the role of 
amphiphilic compounds, salts, proteins and polyelectrolytes in gel swelling behaviour is 
imperative to enhance network functionality, in order to design hydrogel delivery 
systems with control/targeted release profiles. This will, certainly, increase the efficacy 
within current gene therapy trials and it may also be extended to other areas such as 
drug delivery, scaffolds production and tissue engineering. Additionally, the efforts in 
molecular-scale design and in theoretical modelling will, certainly, make the use of 
hydrogels in the biomedical field more feasible and promising. 
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Figure Captions   
 
Figure 1. Picture of plasmid DNA gels cross-linked with 0.2% EGDE.   
Figure 2. Fluorescence micrograph of a plasmid DNA gel (0.2% cross-linker), 
exhibiting a double stranded conformation (A) and scanning electron micrograph of a 
freeze-dried plasmid DNA gel (0.2% cross-linker) (B).     
Figure 3. Swelling isotherms (V/V0) for plasmid DNA gels (0.2% cross-linker) 
immersed in solutions of the cationic surfactants C16TAB, C14TAB, C12TAB and 
C8TAB. Temperature 25ºC, pH 8.5. Adapted from Reference 86.  
Figure 4. Cumulative release of pDNA from cross-linked pDNA gels with 0.2 % () 
and 0.5 % (▲) (w/v) EGDE, as a function of time. Studies were performed after the 
irradiation of gels with light (400 nm) (A) and in the dark conditions (B). Adapted from 
Reference 88.   
Figure 5. Cumulative release of lysozyme, BSA and FITC-dextran from 0.2 % EGDE 
and 0.5 % EGDE plasmid DNA gels as a function of time, and as a function of 0.2 % 
EGDE gel mesh size when gels were irradiated with light (400 nm). Solid lines 
correspond to the best fits of experimental data to equation (2). Adapted from Reference 
88.    
Figure 6. Scanning electron micrograph of plasmid DNA microgels cross-linked with 
0.1% (w/v) EGDE (A) and 0.2% (w/v) EGDE (B). Adapted from Reference 64.    
Figure 7. Quantification of p53 protein expression in cancer HeLa cells using a pan-p53 
Elisa kit, for 0.1 % and 0.2 % (w/v) EGDE cross-linked pDNA microgels (4 or 6 μg/ml 
pDNA loading). The data were obtained by calculating the average of 3 independent 
experiments. The respective errors were determined and were below 0.05 %. Adapted 
from Reference 126.  
Figure 8. Viability of Hela cells after transfection with naked pDNA (6.0 μg/ml) (A), 
0.1% (w/v) EGDE pDNA-lipofectamine microgel (B) or 0.1% (w/v) EGDE 
pDNA/DOX-lipofectamine microgel (C) after 1, 2, 4, 6 and 8 days measured by MTT 
assay. Percent viability is expressed relative to control cells. The data were obtained by 
calculating the average of 3 experiments. The respective errors were determined and 
were below 0.05%.  Adapted from Reference 126. 
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Highlights  
 
∙ Biocompatible macro and micro plasmid DNA gels were prepared by a cross-linking reaction 
for biomedical use.  
 
∙ For the first time, the pDNA gels have been investigated with respect to their swelling 
behaviour in the present of additives; from this, the nature of the interactions can be inferred.     
 
∙ The pDNA based carriers can simultaneously load and release genes and anticancer drugs, 
upon photodegradation, in a controlled and sustained manner.    
 
∙ The combination of chemical and gene therapies has a strong effect in cancer cell apoptosis 
and tumour suppression.  
 
∙ Our cancer therapy approach will inspire researchers to design and develop efficient systems 
for drug/gene co-delivery aiming the challenging cancer cure. 
 
 
 
 
 
